Anti-Coronavirus-Antikörper und Verfahren zur Verwendung

EP3878862 Art A3 6. Oktober 2021

Anmelder: AbCellera Biologics Inc., The United States of America, as represented by The Secretary, Department of Health and Human Services, The United States Of America, As Represented By The Secretary, Department of Health and Human Services 🇨🇦

Details

Veröffentlichungs-Nr.: EP3878862
Aktenzeichen: EP20213900
Anmeldetag: 14. Dezember 2020
Veröffentlichung: 6. Oktober 2021
Rechtsraum: EP
IPC: C07K16/10A61P11/00A61P31/14

Offizieller Volltext

Abstract

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anmelder

Firmen: AbCellera Biologics Inc.
The United States of America, as represented by The Secretary, Department of Health and Human Services
The United States Of America, As Represented By The Secretary, Department of Health and Human Services
Land: 🇨🇦 Kanada

🇺🇸 United States Department of Health and Human Services

US-Bundesministerium, das über seine Behörden (u.a. NIH) medizinische Forschung fördert und daraus resultierende Patente im Namen der US-Regierung hält.

967 Patente in unserer Datenbank

Fachgebiete

Medizintechnik & Gesundheit Organische Chemie

Vertreten von